Shattuck Labs Inc. (STTK)
0.86
-0.03 (-3.71%)
At close: Apr 23, 2025, 3:59 PM
0.82
-4.58%
After-hours: Apr 23, 2025, 07:50 PM EDT
-3.71% (1D)
| Bid | 0.77 |
| Market Cap | 41.37M |
| Revenue (ttm) | 5.72M |
| Net Income (ttm) | -75.41M |
| EPS (ttm) | -1.49 |
| PE Ratio (ttm) | -0.58 |
| Forward PE | -0.98 |
| Analyst | Hold |
| Ask | 0.87 |
| Volume | 114,315 |
| Avg. Volume (20D) | 216,278 |
| Open | 0.90 |
| Previous Close | 0.89 |
| Day's Range | 0.82 - 0.90 |
| 52-Week Range | 0.69 - 11.76 |
| Beta | 1.77 |
About STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorpor...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 9, 2020
Employees 44
Stock Exchange NASDAQ
Ticker Symbol STTK
Website https://www.shattucklabs.com
Analyst Forecast
According to 4 analyst ratings, the average rating for STTK stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 247.34% from the latest price.
Stock Forecasts5 months ago
+12.3%
Shattuck Labs shares are trading higher after the ...
Unlock content with
Pro Subscription
6 months ago
-34.9%
Shattuck Labs shares are trading lower after Needham downgraded the stock from Buy to Hold. Also, Citigroup downgraded the stock form Buy to Neutral and lowered its price target from $8 to $2.
